$27.25
-0.87%BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
BLFS โข NASDAQ
| BioLife Solutions, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Jan 2015 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
96.2M | 82.3M | 75.9M | 76.2M | 119.2M | 48.1M | 27.4M | 19.7M | 11M | 8.2M | 6.4M | 6.2M | 8.9M | 5.7M | 2.8M | 2.1M | 1.6M | 1.3M | 972.3K | 603.2K | |
GROSS PROFIT | ||||||||||||||||||||
(34.1M) | (28.6M) | (96.5M) | (29.3M) | (90.3M) | (20.6M) | (8.9M) | (6.2M) | (4.3M) | (3.4M) | (2.6M) | (3.2M) | (5.2M) | (3.4M) | (1.4M) | (1.2M) | (1M) | (770.6K) | (463.1K) | (298.1K) | |
62.1M | 53.7M | 46.8M | 46.9M | 28.8M | 27.4M | 18.5M | 13.5M | 6.7M | 4.8M | 3.8M | 3M | 3.8M | 2.3M | 1.4M | 856.4K | 574.6K | 551.9K | 509.2K | 305.2K | |
OPERATING INCOME | ||||||||||||||||||||
(74.2M) | (60.8M) | (117.6M) | (52.8M) | (73.3M) | (30.8M) | (18.2M) | (9.9M) | (7.8M) | (9.6M) | (8.8M) | (6.2M) | (4M) | (3.2M) | (2.6M) | (2.3M) | (2.9M) | (3M) | (3.2M) | (1.8M) | |
(55.4M) | (50.2M) | (56M) | (44.9M) | (48.1M) | (21M) | (14.1M) | (8.6M) | (6.6M) | (7.6M) | (7.5M) | (5.3M) | (3.6M) | (2.8M) | (2.1M) | (1.9M) | (2.4M) | (2.6M) | (2.6M) | (1.7M) | |
(7.6M) | (7.9M) | (18.8M) | (14.8M) | (11.8M) | (6.7M) | (4.1M) | (1.3M) | (1.2M) | (2M) | (1.4M) | (871.1K) | (487.8K) | (463.6K) | (516.5K) | (318.9K) | (414.5K) | (457.6K) | (413.4K) | (57.3K) | |
-12.1M | -7.1M | -23.4M | -5.9M | -35.2M | -3.3M | -781K | 3.7M | -1.1M | -4.9M | -5M | -3.1M | -285.4K | -942.2K | -1.2M | -1.4M | -2.3M | -2.5M | -2.7M | -1.5M | |
PRE-TAX INCOME | ||||||||||||||||||||
(2.7M) | (719K) | (1.8M) | (687K) | (485K) | (18K) | (5K) | (5K) | (455K) | (318.4K) | (0.0) | (190.3K) | (742.2K) | (733.4K) | (671K) | (588K) | (488K) | (284.8K) | (138.3K) | (56.5K) | |
-2.7M | -719K | -1.8M | -687K | -485K | 40K | 501K | 276K | -454K | -316K | 21.8K | -169.5K | -798.8K | -812K | -745.4K | -587.8K | -486.9K | -278.4K | 12.1M | -42.8K | |
(11.3M) | (2.7M) | (42.8M) | -6.9M | (13.4M) | (3M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (198.5K) | (0.0) | |
49K | -4.3M | 5M | 1.1M | 6.1M | 5M | -3M | -28.7M | -1.5M | -3.2M | 21.8K | -165.1K | -798.8K | -717.3K | -747K | -589.4K | -481K | -311.7K | -138.3K | 360.3K | |
-12.1M | -11.4M | -18.5M | -4.8M | -29M | -1.3M | 9.5M | 3.3M | -2.5M | -8M | -5M | -3.3M | -1.1M | -1.7M | -2M | -1.4M | -2.8M | -2.5M | -2.9M | -1.1M | |
NET INCOME | ||||||||||||||||||||
(49K) | -38K | (24K) | -5.2M | -20.1M | -3.3M | -1.5M | (396K) | (0.0) | (1.6M) | (0.0) | (0.0) | (0.0) | -368.0 | (0.0) | (3.1K) | -6K | (60.2K) | (0.0) | (0.0) | |
-12.1M | -20.2M | -66.4M | -139.8M | -8.9M | 2.7M | -1.7M | 3.3M | -2.5M | -6.9M | -4.2M | -3.2M | -1.1M | -1.7M | -2M | -2M | -2.8M | -2.8M | -2.9M | -1.1M |
BLFS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 03, 2026 | June 03, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
10-K/A 10-K/A 2025 FY (Amended) FY | April 28, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 02, 2026 | March 02, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 09, 2026 | January 08, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 17, 2025 | November 17, 2025 | 2025 |
Continue your BLFS research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.